Announcements

FCF launches new series of research-focused virtual events

This month, FCF is hosting the first of a series of research-oriented Virtual Open Houses and expert panel discussions focused on the evolution of research and clinical care in FLC. These events are designed to highlight the breadth of fibrolamellar research activity currently underway at leading academic medical centers throughout the country, and to discuss clinical and research topics important to the fibrolamellar community. The first three events are currently on the calendar!

These initial events include:

This Research Virtual Open House is designed to showcase the patient experience and fibrolamellar research activity at the University of Washington, a leading academic medical center. A distinguished panel of experts from UW and a fibrolamellar patient guide the audience through a virtual tour of the patient experience at UW and spotlight their latest fibrolamellar research.

Program highlights:

  • Explore behind-the-scenes research activities at the University of Washington
  • Learn about UW’s latest research developments and how the clinical and research universes intersect
  • Experience the clinical journey through the eyes of a fibrolamellar patient
  • Engage with the panel of experts

Co-hosts:

  • John D. Scott, PhD
    Edwin G. Krebs-Speights Professor of Cell Signaling and Cancer Biology
    Chair, Department of Pharmacology
    University of Washington School of Medicine
  • David Burch
    Fibrolamellar Cancer Foundation Patient Ambassador

Featured panelists:

  • Bill Harris, MD
    Associate Professor, GI Medical Oncology
    University of Washington
    Seattle Cancer Care Alliance
    Fred Hutchinson Cancer Research Center
  • Sophia My-Linh Lauer, PhD Candidate
    Department of Pharmacology
    University of Washington School of Medicine
  • Venu G. Pillarisetty, MD, FACS
    Associate Professor
    HPB Surgical Oncology
    University of Washington School of Medicine
    Medical Director Continuous Performance Improvement, Seattle Cancer Care Alliance
  • Kimberly J. Riehle, MD, FACS, FAAP
    Associate Professor of Surgery, Division of Pediatric General and Thoracic Surgery
    University of Washington
    Seattle Children’s Hospital
  • Alan Utria, MD
    Pediatric Surgery Research Fellow
    University of Washington School of Medicine
  • Raymond S.W. Yeung MD, FRCS (C), FACS
    Professor of Surgery and Director of Liver Tumor Clinic
    University of Washington School of Medicine

Invited audience:

Fibrolamellar patients, caregivers and others interested in learning about FLC research and clinical care at a premier academic medical center are invited. Medical and research professionals are welcome as well.


This event has already been completed.

This on-line panel discussion aims to outline and explore the current state of treatment and patient care for FLC. Panel experts include oncologists, researchers, and surgeons representing both the adult and pediatric fields. 

Panel moderator:

  • Allison O’Neill, MD
    Director, Pediatric Liver Tumor Center of Excellence
    Dana-Farber Cancer Institute
    Boston Children’s Hospital

Featured panelists:

  • James Geller, MD
    Director, Liver, Kidney and Retinoblastoma Programs, Cancer and Blood Disease Institute
    Director, Advanced Cancer Therapy Network, Cancer and Blood Disease Institute
    Director, Pilot Translational Core Grant Program, Center for Clinical and Translational Science and Training
    Professor, UC Department of Pediatrics
    Cincinnati Children’s
  • John Gordan, MD, PhD
    Assistant Professor, Hematology and Oncology
    UCSF Health
  • Erik Schadde, MD, FACS
    Associate Professor, Department of Surgery
    Division of Abdominal Transplantation
    Division of Surgical Oncology
    Rush Medical College
  • Raymond S.W. Yeung MD, FRCS (C), FACS
    Professor of Surgery and Director of Liver Tumor Clinic
    University of Washington School of Medicine

Invited audience:

Any fibrolamellar patients, caregivers and others interested in learning about current approaches to treating FLC are invited. Medical and fibrolamellar research professionals are welcome as well.

This event has already been completed.


This on-line panel discussion explores the role of clinical trials in fibrolamellar carcinoma treatment and the potential evolution of treatment strategies in the future. The event features oncologists from leading institutions, including Dana-Farber Cancer Institute, Johns Hopkins University, MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and Rush University. Specific topics to be covered include:

  • What are clinical trials and why are they so important?
  • What trials are now open for fibrolamellar carcinoma?
  • How does the Food and Drug Administration regulate clinical trials and review new therapeutics and combinations?

Panel moderator:

  • Ghassan Abou-Alfa, MD
    Medical Oncologist
    Gastrointestinal Oncology
    Memorial Sloan Kettering Cancer Center

Featured panelists:

  • Ahmed Kaseb, MD, CMQ
    Professor and Director, Hepatocellular Carcinoma Program
    Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine
    The University of Texas M. D. Anderson Cancer Center
  • Paul Kent, MD, FAAP
    Associate Professor, Hematology and Oncology
    Medical Director Fibrolamellar Carcinoma Program
    Rush University Medical Center
  • Allison O’Neill, MD
    Director, Pediatric Liver Tumor Center of Excellence
    Dana-Farber Cancer Institute
    Boston Children’s Hospital
  • Mark Yarchoan, MD
    Assistant Professor of Oncology
    Johns Hopkins University

Invited audience:

Any fibrolamellar patients, caregivers and others interested in learning about clinical trials are invited. Medical and fibrolamellar research professionals are welcome as well.


Please join us for these events to learn about the exciting advances currently underway in fibrolamellar research and clinical care!